STRASBOURG, France–(BUSINESS WIRE)–Regulatory Information:
Transgene (Euronext Paris: TNG), a biotech firm that designs and develops virus-based immunotherapeutics in opposition to most cancers, at present declares that members of Transgene’s administration and scientific workforce have been invited to take part at upcoming (digital) scientific conferences:
ESMO Focused Anticancer Therapies Congress 2021 which is able to happen March 2-4:
Éric Quéméneur, Government Vice President and Chief Scientific Officer (CSO), will probably be talking within the session ‘The place subsequent with Oncolytics’ about Antibody armed oncolytic viruses (ID 42)
Date & Time: March 3rd at 4.20pm (CET)
4th Annual European Neoantigen Summit which is able to happen April 20-22:
Kaidre Bendjama, Mission Chief, Customized Most cancers Vaccines, will probably be talking about TG4050: Viral immunotherapy meets AI expertise
Date & Time: April 22nd at 1pm (CET)
Transgene (Euronext: TNG) is a biotechnology firm centered on designing and creating focused immunotherapies for the remedy of most cancers. Transgene’s packages make the most of viral vector expertise with the aim of not directly or straight killing most cancers cells.
The Firm’s clinical-stage packages encompass two therapeutic vaccines (TG4001 for the remedy of HPV-positive cancers, and TG4050, the primary individualized therapeutic vaccine primarily based on the myvac® platform) in addition to two oncolytic viruses (TG6002 for the remedy of strong tumors, and BT-001, the primary oncolytic virus primarily based on the Invir.IO™ platform).
With Transgene’s myvac® platform, therapeutic vaccination enters the sector of precision medication with a novel immunotherapy that’s totally tailor-made to every particular person. The myvac® strategy permits the era of a virus-based immunotherapy that encodes patient-specific mutations recognized and chosen by Synthetic Intelligence capabilities offered by its accomplice NEC.
With its proprietary platform Invir.IO™, Transgene is constructing on its viral vector engineering experience to design a brand new era of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.
This press launch comprises forward-looking statements, that are topic to quite a few dangers and uncertainties, which may trigger precise outcomes to vary materially from these anticipated. The incidence of any of those dangers may have a major unfavourable final result for the Firm’s actions, views, monetary state of affairs, outcomes, regulatory authorities’ settlement with growth phases, and growth. The Firm’s capacity to commercialize its merchandise is dependent upon however will not be restricted to the next elements: optimistic pre-clinical knowledge will not be predictive of human scientific outcomes, the success of scientific research, the power to acquire financing and/or partnerships for product manufacturing, growth and commercialization, and advertising approval by authorities regulatory authorities. For a dialogue of dangers and uncertainties which may trigger the Firm’s precise outcomes, monetary situation, efficiency or achievements to vary from these contained within the forward-looking statements, please consult with the Threat Components (“Facteurs de Risque”) part of the Common Registration Doc, obtainable on the AMF web site (http://www.amf-france.org) or on Transgene’s web site (www.transgene.fr). Ahead-looking statements communicate solely as of the date on which they’re made and Transgene undertakes no obligation to replace these forward-looking statements, even when new info turns into obtainable sooner or later.